Plaintiff Regla F. has filed a diabetic ketoacidosis complications lawsuit against the manufacturers of Invokana after allegedly suffering from severe adverse effects and complications from taking the medication.

She files the diabetic ketoacidosis complications lawsuit against manufacturers and defendants Janssen Pharmaceuticals Inc. and its parent company Johnson & Johnson.

According to the diabetic ketoacidosis complications lawsuit, Regla is a citizen and resident of New York state. She alleges that she began taking Invokana in July 2014 and continued to take the medication through June 2015.

Regla contends that she began taking Invokana medication as prescribed and directed to her by her physician.

However, according to the diabetic ketoacidosis complications lawsuit, after less than one year of taking Invokana medication, she was admitted to Wilson Memorial Regional Medical center in Johnson City, N.Y. in January 2015, with symptoms of nausea, vomiting and pain. She was later diagnosed with diabetic ketoacidosis.

According to the diabetic ketoacidosis complications lawsuit, Regla “endured pain and suffering, emotional distress, loss of enjoyment of life, and economic loss, including significant expenses for medical care and treatment.”

She seeks damages from the defendants including compensatory, actual, and punitive damages.

Risk of Diabetic Ketoacidosis Complications

Regla’s claim is filed as part of a large multidistrict litigation, or MDL, centered on allegations that Invokana medication causes diabetic ketoacidosis, among other severe adverse effects and complications.

Invokana is a popular prescribed medication for the treatment of type-2 diabetes. Invokana, Invokamet and Invokamet XR are from a class of type-2 diabetes medications that have allegedly caused adverse effects and complications including diabetic ketoacidosis and lower extremity amputations.

This class of drugs is called sodium-glucose contransporter-2 (SGLT-2) inhibitors. In an announcement made by the U.S. Food and Drug Administration (FDA) in May 2017, the agency warned against increased risks of adverse effects and complications with these drugs.

According to the FDA, “Based on new data from two large clinical trials, the [FDA] has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.”

The Diabetic Ketoacidosis Complications Lawsuit is Case No. 3:17-cv-10269-BRM-LHG and is part of the Invokana MDL, is In re: Invokana (Canagliflozin) Products Liability Litigation, MDL 2750, in the U.S. District Court for the District of New Jersey.